Literature DB >> 23047058

Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure.

R J McLaughlin1, M N Hill, S S Dang, S R Wainwright, L A M Galea, C J Hillard, B B Gorzalka.   

Abstract

Accumulating evidence has revealed that dysregulation of the endocannabinoid system could contribute to the development of major depression. Studies carried out post-mortem in depressed suicide victims have revealed increased CB(1) receptor binding site density in the prefrontal cortex (PFC). Accordingly, exposure of rodents to chronic unpredictable stress (CUS) results in phenotypic changes that mirror those of human depression, including increased CB(1) receptor binding site density in the PFC. Our goal in these studies was to examine the effects of CUS on the density of CB(1) receptor binding sites in the rodent medial PFC and to explore the role of this alteration in the behavioral changes invoked by CUS. Rodents exposed to CUS exhibited increased CB(1) receptor maximal binding site density (B(max)) within the ventromedial PFC, but not the dorsomedial PFC. To determine whether this change in the ventromedial PFC is an adaptive response, or alternatively, a consequence of chronic stress that contributes to the adoption of passive coping, we examined whether local CB(1) receptor blockade within the ventromedial PFC following CUS would significantly alter behaviors in the forced swim test (FST). CUS exposure significantly increased passive coping in the FST, and this was further augmented by discrete ventromedial PFC microinfusions of the CB(1) receptor antagonist AM251 prior to swim stress. Moreover, local CB(1) receptor blockade reduced active coping responses in CUS-exposed rats. These findings suggest that the increase in CB(1) receptor B(max) observed in the ventromedial PFC of rodents exposed to CUS maintains proactive coping strategies following chronic stress exposure.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23047058      PMCID: PMC3501995          DOI: 10.1016/j.bbr.2012.09.053

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  33 in total

Review 1.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

2.  Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure.

Authors:  M N Hill; S A Kumar; S B Filipski; M Iverson; K L Stuhr; J M Keith; B F Cravatt; C J Hillard; S Chattarji; B S McEwen
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

3.  Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice.

Authors:  David J Rademacher; Sarah E Meier; Leyu Shi; W-S Vanessa Ho; Abbas Jarrahian; Cecilia J Hillard
Journal:  Neuropharmacology       Date:  2007-06-29       Impact factor: 5.250

4.  Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear.

Authors:  Kwang Choi; Thien Le; Jennifer McGuire; Guoqiang Xing; Lei Zhang; He Li; Clarissa C Parker; Luke R Johnson; Robert J Ursano
Journal:  J Psychiatr Res       Date:  2012-04-23       Impact factor: 4.791

Review 5.  Cannabinoids and emotionality: a neuroanatomical perspective.

Authors:  R J McLaughlin; G Gobbi
Journal:  Neuroscience       Date:  2011-07-27       Impact factor: 3.590

Review 6.  Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants.

Authors:  Boris B Gorzalka; Matthew N Hill
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-11-24       Impact factor: 5.067

7.  Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.

Authors:  Takaki Kiritoshi; Hao Sun; Wenjie Ren; Shaun R Stauffer; Craig W Lindsley; P Jeffrey Conn; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2012-04-06       Impact factor: 5.250

8.  Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response.

Authors:  Matthew N Hill; Ryan J McLaughlin; Bin Pan; Megan L Fitzgerald; Christopher J Roberts; Tiffany T-Y Lee; Ilia N Karatsoreos; Ken Mackie; Victor Viau; Virginia M Pickel; Bruce S McEwen; Qing-song Liu; Boris B Gorzalka; Cecilia J Hillard
Journal:  J Neurosci       Date:  2011-07-20       Impact factor: 6.167

9.  Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway.

Authors:  Ryan J McLaughlin; Matthew N Hill; Francis R Bambico; Kara L Stuhr; Gabriella Gobbi; Cecilia J Hillard; Boris B Gorzalka
Journal:  Eur Neuropsychopharmacol       Date:  2012-02-10       Impact factor: 4.600

10.  Architectonic subdivision of the human orbital and medial prefrontal cortex.

Authors:  Dost Ongür; Amon T Ferry; Joseph L Price
Journal:  J Comp Neurol       Date:  2003-06-02       Impact factor: 3.215

View more
  20 in total

1.  The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System.

Authors:  Anthony L Berger; Angela M Henricks; Janelle M Lugo; Hayden R Wright; Collin R Warrick; Martin A Sticht; Maria Morena; Itziar Bonilla; Sarah A Laredo; Rebecca M Craft; Loren H Parsons; Pedro R Grandes; Cecilia J Hillard; Matthew N Hill; Ryan J McLaughlin
Journal:  Biol Psychiatry       Date:  2018-05-08       Impact factor: 13.382

Review 2.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 3.  Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.

Authors:  Nicholas B Worley; Matthew N Hill; John P Christianson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-04-07       Impact factor: 5.067

Review 4.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

5.  CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats.

Authors:  Jayme R McReynolds; Elizabeth M Doncheck; Oliver Vranjkovic; Geoffrey S Ganzman; David A Baker; Cecilia J Hillard; John R Mantsch
Journal:  Psychopharmacology (Berl)       Date:  2015-10-12       Impact factor: 4.530

6.  Monoacylglycerol lipase alpha inhibition alters prefrontal cortex excitability and blunts the consequences of traumatic stress in rat.

Authors:  N B Worley; J A Varela; G P Gaillardetz; M N Hill; J P Christianson
Journal:  Neuropharmacology       Date:  2020-01-16       Impact factor: 5.250

Review 7.  Endocannabinoid signaling in the etiology and treatment of major depressive illness.

Authors:  Cecilia J Hillard; Qing-song Liu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 8.  Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors.

Authors:  Srinagesh Mannekote Thippaiah; Sloka S Iyengar; K Yaragudri Vinod
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

Review 9.  Prefrontal cortex and depression.

Authors:  Diego A Pizzagalli; Angela C Roberts
Journal:  Neuropsychopharmacology       Date:  2021-08-02       Impact factor: 7.853

10.  Chronic unpredictable stress during adolescence protects against adult traumatic brain injury-induced affective and cognitive deficits.

Authors:  Patricia B de la Tremblaye; JoDy L Wellcome; Kaitlyn Wiley; Carolyn A Lomahan; Eleni H Moschonas; Jeffrey P Cheng; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2021-06-04       Impact factor: 3.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.